« SocialFlickrtextgoo |
Main
| Numenta for Neurotechnology - Now That's Valuable »
March 23, 2005
Saegis Continues Cogniceutical Progress with ADHD Focus
Posted by Zack Lynch
Cogniceuticals improve and treat disorders of attention, learning, memory, or cognition. Cogniceuticals are the fastest growing neuropharmaceutical market for two primary reasons: (1) demographic shifts towards aging population (2) scientific progress on memory related disorders, especially animal models.
As I wrote last year in Saegis a cogniceutical pure play, Saegis continues to prove their cogniceutical focus with their recent announcement that it began a Phase II study of its lead product candidate, SGS742, for adult patients with attention deficit hyperactivity disorder. It's progress and focus like this that have made the neurotechnology industry one of the hottest areas for venture capital investment in the life sciences, surging 225% in the past 5 years.
Comments (0)
+ TrackBacks (0) | Category: Cogniceuticals
- RELATED ENTRIES
- NIO Unveils Top 10 Neuroscience Trends for 2009
- NIO CEO Media Tour in NYC Gets Results
- O Neurocaster
- Manuscript Sent to Japan
- 2009 Stem Cell Trendsetters in Neurology and Psychiatry
- Mental Health Parity Legislation Passes within Financial Package
- Holy Neurofinancial Meltdown Bernanke
- Interest in Neuropolicy Grows